Robert W. Baird Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its price objective hoisted by investment analysts at Robert W. Baird from $46.00 to $48.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 15.86% from the stock’s current price.

Several other equities research analysts have also recently commented on the company. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.44.

Twist Bioscience Price Performance

NASDAQ TWST opened at $41.43 on Tuesday. The business has a 50 day simple moving average of $43.98 and a 200 day simple moving average of $46.18. Twist Bioscience has a one year low of $23.00 and a one year high of $60.90. The stock has a market capitalization of $2.43 billion, a P/E ratio of -10.85 and a beta of 1.78.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 1,057 shares of Twist Bioscience stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the sale, the senior vice president now directly owns 121,013 shares in the company, valued at approximately $5,029,300.28. This trade represents a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 over the last 90 days. Insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently bought and sold shares of TWST. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience during the third quarter worth $43,992,000. Point72 Asset Management L.P. raised its stake in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after buying an additional 613,057 shares during the period. Fred Alger Management LLC raised its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after buying an additional 575,080 shares during the period. State Street Corp raised its stake in shares of Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.